Baroness Finlay of Llandaff

Deputy Speaker (Lords)

Crossbench Peer

Proffil

Crossbench Arglwydd

Aeth i mewn i'r Tŷ'r Arglwyddi ar 10 Gorffennaf 2001

Swyddogaethau cyfredol

  • Member, Delegated Powers and Regulatory Reform Committee (since 31 Ion 2024)
  • Member, Standing Orders (Private Bills) Committee (Lords) (since 22 Chw 2022)
  • Deputy Speaker (Lords) (since 5 Maw 2018)
  • Deputy Chairman of Committees (since 6 Tach 2017)

Swyddogaethau eraill yn y gorffennol

  • Member, Integration of Primary and Community Care Committee (31 Ion 2023 to 27 Tach 2023)
  • Member, Procedure and Privileges Committee ( 1 Gor 2019 to 31 Ion 2023)
  • Member, National Policy for the Built Environment Committee (11 Meh 2015 to 11 Chw 2016)
  • Member, Public Service and Demographic Change Committee (29 Mai 2012 to 5 Maw 2013)
  • Member, Select Committee on Science and Technology Sub-Committee 2 (14 Tach 2007 to 12 Tach 2009)
  • Member, Committee on the Assisted Dying for the terminally ill Bill (30 Tach 2004 to 7 Ebr 2005)
  • Member, Draft Mental Health Bill (Joint Committee) (22 Gor 2004 to 11 Gor 2005)
  • Member, Science and Technology Committee (Lords) (19 Tach 2002 to 30 Hyd 2007)
  • Member, Science and Technology: Sub-Committee I (13 Tach 2002 to 30 Hyd 2007)
  • Member, Select Committee on Science and Technology Sub-Committee 2 (13 Tach 2002 to 17 Tach 2005)

Ymddangosiadau diweddar

  • Covid-19 Vaccination: Coronary Disease - Question 23 Apr 2024

    My Lords, does the Minister agree that, although we are talking about heart disease, we must also remember pulmonary embolism from clotting disorders, which can persist for up to six months after even a mild Covid infection? A massive pulmonary embolus is another cause of mortality in people who have Covid. One of the problems with the virus is its ability to mutate, but the evidence is that...
  • Written Answers — Department of Health and Social Care: Tofersen: Licensing 22 Apr 2024

    To ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK.
  • Written Answers — Department of Health and Social Care: Tofersen: Licensing 22 Apr 2024

    To ask His Majesty's Government what consideration was given to the costs of complicated grief in families of patients dying from SOD-1 MND during the evaluation process that led to the decision to decline access to tofersen for NHS patients.

Mwy o ymddangosiadau diweddar Baroness Finlay of Llandaff

RSS feed (?)

Nodyn ar gyfer newyddiadurwyr ac ymchwilwyr: gellir defnyddio'r data ar y dudalen hon yn rhydd, ar yr amod bod TheyWorkForYou.com yn cael ei ddyfynnu fel y ffynhonnell.

Cynhyrchwyd y data yma gan TheyWorkForYou o amrywiaeth o ffynonellau. Gwybodaeth bleidleisio o Chwip Cyhoeddus.

Llun proffil: © Parliament (CC-BY 3.0)